We have designed KD033 to target IL-15 to PD-L1+ tumors and to bring cytotoxic cells to the tumor-microenvironment; therefore, the observation that KD033 and KD033-surrogate had significant anti-tumor efficacies and comparable tumor-growth inhibitions for both PD-L1+ and PD-L1- tumors was unexpected. This evidence concerns the gene CD274 and neoplasm.